Non-GMP
Supporting Risk-based GMP Implementation
For early phase programs under time and quality pressures, Dasha Pharma has implemented a risk-based non-GMP approach that includes a road map that incorporates increased GMP over time. The flexibility to include non-GMP solutions, considers the client’s immediate needs as well as the longer term commercial requirements.
Our cross-functional team from process development, quality and regulatory affairs have substantial experience in successfully introducing chemical steps from non-GMP to GMP scale up and thus driving small molecules APIs or drug products to commercialization with full regulatory compliance.
Expert counsel for GMP requirement determination
- Fast delivery to move the project forward
- Maximum flexibility and better budget control for early phase projects
- Clear understanding of phase appropriate regulatory requirements
- 300 MT’s facility capacity dedicated to Manufacturing & R&D
- Back integrationof large scale hard-to-find raw material non-GMP production
